BGM0504
Sources
registry, as of 2026-10-15Stale
https://clinicaltrials.gov/study/NCT06704581
A Study of BGM0504 Injection in Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.. Enrollment 652. Conditions Overweight or Obesity. This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an
ClinicalTrials.gov NCT06704581 protocol and results modules
registry, as of 2026-10-15Stale
https://clinicaltrials.gov/study/NCT07658560
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes. Overall status RECRUITING. Phases PHASE2. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 200. Conditions Overweight or Obese Participants Without Diabetes. To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.
ClinicalTrials.gov NCT07658560 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT06973681
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 120. Conditions Overweight or Obesity. To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
ClinicalTrials.gov NCT06973681 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT06911203
A Study of BGM0504 in Participants With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 96. Conditions Obesity. To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
ClinicalTrials.gov NCT06911203 protocol and results modules
registry, as of 2026-09-23Stale
https://clinicaltrials.gov/study/NCT07836140
A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.. Overall status COMPLETED. Phases PHASE2. Lead sponsor Second Affiliated Hospital of Soochow University. Enrollment 60. Conditions Obesity / Overweight. An Investigator-Initiated, Randomized, Open-Label, Active-Controlled Study Comparing the Effects of BGM0504 Injection versus Semaglutide Injection on Insulin Sensitivity and Body Weight in Obese Subjects
ClinicalTrials.gov NCT07836140 protocol and results modules
registry, as of 2026-10-16Stale
https://clinicaltrials.gov/study/NCT07382908
Bioequivalence Study of BGM0504 Injection. Overall status COMPLETED. Phases PHASE1. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 144. Conditions Overweight/Obesity. This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).
ClinicalTrials.gov NCT07382908 protocol and results modules
registry, as of 2026-10-19Stale
https://clinicaltrials.gov/study/NCT07166081
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 80. Conditions Non-diabetic Overweight or Obese. This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweigh
ClinicalTrials.gov NCT07166081 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07239973
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 75. Conditions Healthy; Non-diabetic Overweight or Obese. A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
ClinicalTrials.gov NCT07239973 protocol and results modules
publication, as of 2026-11-03
https://pubmed.ncbi.nlm.nih.gov/42755112/
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. To evaluate the safety, tolerability, ph
PMID 42755112